Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC)
AffiliationDepartment of Immunology, Faculty of Health Sciences, University of Pretoria , Pretoria, South Africa.
MetadataShow full item record
AbstractIntroduction: Patients with hematological and advanced solid malignancies have acquired immune dysfunction, often exacerbated by treatment, posing a significant risk for development of infections. This review evaluates the utility of current clinical and treatment guidelines, in the setting of management of infections in cancer patients. Areas covered: : These include causes of infection in cancer patients, management of patients with high-risk and low-risk febrile neutropenia, management of low-risk patients in an outpatient setting, the role of granulocyte colony-stimulating factor (G-CSF) in the prevention and treatment of neutropenia-related infections, management of lung infections in various clinical settings, and emerging challenges surrounding the risk of infection in cancer patients treated with novel treatments. The literature search was performed by accessing PubMed and other databases, focusing on published clinical trials of relevant anti-cancer agents and diseases, primarily covering the recent past, but also including several key studies published during the last decade and, somewhat earlier in a few cases. Expert review: Notwithstanding the promise of gene therapy/gene editing in hematological malignancies and some types of solid cancers, innovations introduced in clinical practice include more discerning clinical management such as the generalized use of biosimilar formulations G-CSF and the implementation of novel, innovative immunotherapies.
CitationRapoport BL, Cooksley T, Johnson DB, Anderson R, Shannon VR. Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC). Expert Rev Clin Pharmacol. 2021.
JournalExpert Review of Clinical Pharmacology
- Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
- Authors: Skoetz N, Bohlius J, Engert A, Monsef I, Blank O, Vehreschild JJ
- Issue date: 2015 Dec 21
- Colony-stimulating factors for the management of neutropenia in cancer patients.
- Authors: Dale DC
- Issue date: 2002
- Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
- Authors: Mitchell S, Li X, Woods M, Garcia J, Hebard-Massey K, Barron R, Samuel M
- Issue date: 2016 Oct
- The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia.
- Authors: Klastersky J, Raftopoulos H, Rapoport B
- Issue date: 2013 Jun
- Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.
- Authors: Barnes G, Pathak A, Schwartzberg L
- Issue date: 2014 Jul